CN101102786A - 施用并利用vegf抑制剂治疗人类癌症的方法 - Google Patents

施用并利用vegf抑制剂治疗人类癌症的方法 Download PDF

Info

Publication number
CN101102786A
CN101102786A CNA2005800189582A CN200580018958A CN101102786A CN 101102786 A CN101102786 A CN 101102786A CN A2005800189582 A CNA2005800189582 A CN A2005800189582A CN 200580018958 A CN200580018958 A CN 200580018958A CN 101102786 A CN101102786 A CN 101102786A
Authority
CN
China
Prior art keywords
cancer
vegf
use according
flt
initial dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800189582A
Other languages
English (en)
Chinese (zh)
Inventor
J·M·塞德鲍姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN101102786A publication Critical patent/CN101102786A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CNA2005800189582A 2004-06-10 2005-06-10 施用并利用vegf抑制剂治疗人类癌症的方法 Pending CN101102786A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57849904P 2004-06-10 2004-06-10
US60/578,499 2004-06-10

Publications (1)

Publication Number Publication Date
CN101102786A true CN101102786A (zh) 2008-01-09

Family

ID=35510259

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800189582A Pending CN101102786A (zh) 2004-06-10 2005-06-10 施用并利用vegf抑制剂治疗人类癌症的方法

Country Status (9)

Country Link
US (7) US7354580B2 (enExample)
EP (2) EP1753442A2 (enExample)
JP (2) JP2008502738A (enExample)
CN (1) CN101102786A (enExample)
AU (1) AU2005254058A1 (enExample)
CA (1) CA2567686A1 (enExample)
IL (1) IL179515A0 (enExample)
MX (1) MXPA06014421A (enExample)
WO (1) WO2005123104A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102265157A (zh) * 2008-12-23 2011-11-30 霍夫曼-拉罗奇有限公司 用于癌症患者中诊断用途的方法和组合物
CN104004058A (zh) * 2014-06-23 2014-08-27 苏州普罗达生物科技有限公司 有关白介素-33抑制剂多肽及其应用
CN108496084A (zh) * 2016-01-25 2018-09-04 赛诺菲 通过测量血浆生物标记的水平预测疑似患有癌症的患者使用阿柏西普的治疗的结果的方法

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1755645A2 (en) * 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
ES2633574T3 (es) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
AU2006279658A1 (en) 2005-08-12 2007-02-22 Regeneron Pharmaceuticals, Inc. Treatment of diseases by subcutaneous administration of a VEGF antagonist
US8093259B2 (en) * 2006-05-25 2012-01-10 Novartis Ag 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma
PT2944306T (pt) 2006-06-16 2021-02-15 Regeneron Pharma Formulações antagonistas de vegf adequadas para administração intravitreal
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
SI2066694T1 (sl) 2006-09-29 2016-02-29 Oncomed Pharmaceuticals, Inc. Sestavki in postopki za diagnosticiranje in zdravljenje raka
AU2014201795B2 (en) * 2006-12-19 2016-05-19 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
BRPI0720552A2 (pt) * 2006-12-19 2014-01-07 Genentech Inc Antagonistas específicos de vegf para terapia adjuvante e neoadjuvante e o tratamento de tumores em estágio precoce
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
CN102480957A (zh) 2009-05-27 2012-05-30 Ptc医疗公司 治疗癌症及非肿瘤病症的方法
TR201818814T4 (tr) 2009-10-16 2019-01-21 Oncomed Pharm Inc Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı.
CA2804348A1 (en) * 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
BR112013017752A8 (pt) 2011-01-13 2018-01-09 Regeneron Pharma uso de um antagonista do vegf e formulação farmacêutica
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
PT3485903T (pt) 2011-09-23 2023-02-17 Mereo Biopharma 5 Inc Agentes de ligação a vegf/dll4 e utilizações dos mesmos
CA2889638A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
MY170528A (en) 2013-02-18 2019-08-09 Vegenics Pty Ltd Vegfr-3 ligand binding molecules and uses thereof
JP6071099B1 (ja) 2014-01-25 2017-02-01 ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド 血管の新生又は成長を抑制する融合タンパク質及びその用途
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
PT3170005T (pt) 2014-07-18 2019-07-16 Sanofi Sa Método para a previsão do resultado de um tratamento com aflibercept de um paciente suspeito de sofrer de um cancro
ES2808153T3 (es) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Terapia de combinación para tratamiento de enfermedad
KR20170082537A (ko) * 2014-11-14 2017-07-14 제넨테크, 인크. Vegf 길항제에 대한 반응 예측
AU2016326609B2 (en) 2015-09-23 2023-03-09 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
CA3014888A1 (en) 2016-02-18 2017-08-24 University Of Massachusetts Combination therapy
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
CN110945025B (zh) * 2017-03-30 2023-11-03 Ecs前胃泌素股份有限公司 用于检测前列腺癌的组合物和方法
EP3664803A4 (en) * 2017-08-01 2021-05-05 PTC Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
CN111343984A (zh) * 2017-10-24 2020-06-26 Md Bio有限公司 包含链黑菌素及雷帕霉素作为有效成分的癌症预防或治疗用药学组合物
EP3716992B1 (en) 2017-11-30 2022-08-10 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
SG11202007130RA (en) 2018-01-26 2020-08-28 Univ California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
KR102387564B1 (ko) * 2018-11-20 2022-04-18 (주)엠디바이오랩 스트렙토니그린 및 항암제를 모두 포함하는 암 예방 또는 치료용 약학적 조성물
WO2020159203A1 (ko) * 2019-01-29 2020-08-06 (주)엠디바이오랩 스트렙토니그린 및 항암제를 포함하는 뇌종양 예방 또는 치료용 조성물
KR102358632B1 (ko) * 2019-02-01 2022-02-04 (주)엠디바이오랩 스트렙토니그린 및 항암제를 포함하는 대장암 예방 또는 치료용 약학적 조성물
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
US20220196166A1 (en) * 2020-12-18 2022-06-23 Nibco Inc. L-ball union drain valve
US11898643B1 (en) 2022-12-28 2024-02-13 Nibco Inc. Dual union ball drain valve with T-flow adjustability
US12140236B2 (en) 2023-02-08 2024-11-12 Nibco Inc. Dual union drain valve with reversible check inserts

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7264801B2 (en) * 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
BRPI0011407B8 (pt) 1999-06-08 2021-05-25 Regeneron Pharma molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
JP2007529418A (ja) * 2003-05-28 2007-10-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆアンタゴニストの使用による角膜移植拒絶を処置する方法
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7354578B2 (en) * 2003-06-06 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of tumor regression with VEGF inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102265157A (zh) * 2008-12-23 2011-11-30 霍夫曼-拉罗奇有限公司 用于癌症患者中诊断用途的方法和组合物
CN102265157B (zh) * 2008-12-23 2014-11-26 霍夫曼-拉罗奇有限公司 用于癌症患者中诊断用途的方法和组合物
CN104004058A (zh) * 2014-06-23 2014-08-27 苏州普罗达生物科技有限公司 有关白介素-33抑制剂多肽及其应用
CN108496084A (zh) * 2016-01-25 2018-09-04 赛诺菲 通过测量血浆生物标记的水平预测疑似患有癌症的患者使用阿柏西普的治疗的结果的方法

Also Published As

Publication number Publication date
WO2005123104A2 (en) 2005-12-29
US20080214465A1 (en) 2008-09-04
US20050276808A1 (en) 2005-12-15
IL179515A0 (en) 2007-05-15
JP2012067116A (ja) 2012-04-05
US20080188420A1 (en) 2008-08-07
US20080171703A1 (en) 2008-07-17
US7479272B2 (en) 2009-01-20
US7479273B2 (en) 2009-01-20
US20080214466A1 (en) 2008-09-04
US20080188418A1 (en) 2008-08-07
US7482001B2 (en) 2009-01-27
US7482002B2 (en) 2009-01-27
US7479274B2 (en) 2009-01-20
JP2008502738A (ja) 2008-01-31
MXPA06014421A (es) 2007-05-04
EP1753442A2 (en) 2007-02-21
CA2567686A1 (en) 2005-12-29
US20080188419A1 (en) 2008-08-07
US7479275B2 (en) 2009-01-20
EP2583685A1 (en) 2013-04-24
WO2005123104A3 (en) 2006-04-27
AU2005254058A1 (en) 2005-12-29
US7354580B2 (en) 2008-04-08

Similar Documents

Publication Publication Date Title
CN101102786A (zh) 施用并利用vegf抑制剂治疗人类癌症的方法
US10981973B2 (en) Methods of treating a sclerotic disorder by administering a transforming growth factor beta receptor type II fusion polypeptide
KR101718748B1 (ko) Ｉｌ-6 수용체의 길항에 의한 종양 성장의 저해 방법
KR102338453B1 (ko) Ｖｅｇｆ 길항제와 항-ｃｔｌａ-4 항체의 조합물을 포함하는 조성물 및 방법
KR101175990B1 (ko) Ｖｅｇｆ 길항제와 항증식성 제제의 조성물
CN113171442B (zh) Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
KR101774272B1 (ko) Ｗｎｔ 길항약 및 치료와 스크리닝 방법
KR102079482B1 (ko) 비효율적 적혈구생성 치료를 위한 방법 및 조성물
US20040265309A1 (en) Method of tumor regression with VEGF inhibitors
KR101819135B1 (ko) 당화 vegf 디코이 수용체 융합 단백질
KR20080033390A (ko) Ｖｅｇｆ 길항제로 질병을 치료하는 방법
CN1968709A (zh) 用于治疗恶性胸腔积液的vegf抑制剂
KR20120049214A (ko) 발열성 지방세포를 증가시키는 방법
CA2952231A1 (en) Formulated receptor polypeptides and related methods
TW201010715A (en) FGF21 mutants and uses thereof
KR20150082327A (ko) Ｄｌｌ4 길항제로 난소암을 치료하는 방법
CN1997386A (zh) 通过阻断vegf介导的活性来治疗i型糖尿病的方法
HK1116053A (en) Use of vegf inhibitors for the treatment of human cancer
AU2022221660A1 (en) Multi-domain fusion protein and use thereof
HK1224576A1 (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1116053

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080109

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1116053

Country of ref document: HK